» Articles » PMID: 10673188

Induced Sputum Cell Counts in Healthy Adults

Overview
Specialty Critical Care
Date 2000 Feb 15
PMID 10673188
Citations 91
Authors
Affiliations
Soon will be listed here.
Abstract

Induced sputum cell counts provide a relatively noninvasive method to evaluate the presence, type, and degree of inflammation in the airways of the lungs. Their interpretation requires a knowledge of normal values from a healthy population. The objective was to examine the total and differential cell counts in induced sputum from a sample of healthy adults. A total of 118 healthy nonsmoking adults were studied. None had asthma or airflow obstruction (negative history, FEV(1) >/= 80% predicted, ratio of FEV(1) to vital capacity [FEV(1)/VC] >/= 80%, methacholine PC(20) >/= 16 mg/ml). Forty-six were atopic. Sputum induction produced an adequate sample in 96 subjects [53 males, mean age (range) 36 (18 to 60) yr]. The expectorate was processed within 2 h; sputum was selected, treated with dithiothreitol, filtered, and examined in a hemocytometer for total cell count and viability and on Wright-stained cytospins for a differential cell count. The mean, median (90th percentile) total cell count was 4.1, 2.4 (9.7) x 10(6) cells/g and cell viability was 69.6, 72.0 (89.7)%. The proportions of eosinophils were 0.4, 0.0 (1.1)%, neutrophils 37.5, 36.7 (64.0)%, macrophages 58.8, 60.8 (86.1)%, lymphocytes 1.0, 0.5 (2.6)%, metachromatic cells 0.0, 0.0 (0.04)%, and bronchial epithelial cells 1.6, 0.3 (4.4)%, respectively. Female gender and atopy were associated with a significant elevation of eosinophils; mean difference between male/female was 0.3% (p = 0.043) and between atopic/nonatopic 0.4% (p = 0.024). This study has identified reference values for total and differential cell counts in induced sputum of healthy adults.

Citing Articles

Biomarkers of genotoxic damage in pulmonary alveolar macrophages: a review.

DAgostini F, La Maestra S Arch Toxicol. 2024; 99(1):211-224.

PMID: 39453481 DOI: 10.1007/s00204-024-03894-0.


New targets for type 2-low asthma.

Luu Quoc Q, Choi Y, Hur G, Park H Korean J Intern Med. 2024; 39(2):215-227.

PMID: 38317271 PMC: 10918384. DOI: 10.3904/kjim.2023.299.


Sputum induction and its diagnostic applications in inflammatory airway disorders: a review.

Goncalves B, Eze U Front Allergy. 2023; 4:1282782.

PMID: 37901763 PMC: 10600502. DOI: 10.3389/falgy.2023.1282782.


How inhaled corticosteroids target inflammation in COPD.

Lea S, Higham A, Beech A, Singh D Eur Respir Rev. 2023; 32(170).

PMID: 37852657 PMC: 10582931. DOI: 10.1183/16000617.0084-2023.


Development of Adaptive Immunity and Its Role in Lung Remodeling.

Esnault S, Jarjour N Adv Exp Med Biol. 2023; 1426:287-351.

PMID: 37464127 DOI: 10.1007/978-3-031-32259-4_14.